ResMed Inc (RMD) Cotización

News; $RMD ResMed (RMD) Q1 2021 Earnings Call Transcript

Image source: The Motley Fool. ResMed (NYSE: RMD) Q1 2021 Earnings Call Oct 29, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: ResMed (RMD) Q1 2021 Earnings Call Transcript

Find out more RMD - ResMed (RMD) Q1 2021 Earnings Call Transcript

RMD was just on Cramers MAd mONEy tonight

News: $RMD Why ResMed Stock Is Shooting Higher Today

After management reported fiscal 2020 first-quarter results , shares of ResMed (NYSE: RMD) , a medical device maker focused on sleep-disorder breathing, rose 12% as of 12:00 p.m. EDT on Friday. The headline numbers from the period were great: Traders sent the share price to a new all-time ...

In case you are interested RMD - Why ResMed Stock Is Shooting Higher Today

News: $RMD How ResMed Blew Past Expectations With Its Q1 Results

Despite a horrible start, 2019 has turned out to be a reasonably good year so far for ResMed (NYSE: RMD) . The healthcare company has consistently beaten Wall Street earnings estimates in recent quarters and delivered solid growth. ResMed announced its fiscal 2020 first-quarter results after...

Got this from RMD - How ResMed Blew Past Expectations With Its Q1 Results

100+ tomorrow.

100

ResMed $RMD has little Margin of Safety for value investors before earnings Monday:

Fair Value Analysis

Medical Device Maker Delivers Wake-Up Call
MANUFACTURING: ResMed, Major Rival Team Up to Educate Clinicians About Sleep Disorders

In addition to announcing record revenues recently, ResMed is teaming up with a major competitor to educate the medical community in a $1 million campaign to help reach millions of undiagnosed Americans with sleeping disorders, especially sleep apnea.

Company officials said Sept. 30 that the campaign with Respironics, another device maker, and Cephalon, a drug company, is a wake-up call to action for a public health threat that the U.S. Department of Health & Human Services said results in an estimated $16 billion annually in medical costs, not including costs associated with lost work time.

http://www.sdbj.com/news/2010/oct/11/medical-device-maker-delivers-wake-call/

SYDNEY (Dow Jones)--Sleep disorder device company ResMed Inc. (RMD.AU) has agreed to revise its internal fair-trading checks following an investigation of price-fixing by Australia's competition regulator.

The Australian Competition and Consumer Commission said Tuesday it had investigated the company over whether it was telling accredited retailers that it would stop supplying its products if they sold them at less than a price specified by ResMed, a practice known as retail price maintenance.

"The ACCC is concerned that between March and June 2009 ResMed is likely to have engaged in retail price maintenance," the ACCC said in a statement.

ResMed has accepted a court-enforceable undertaking to write to its accredited retailers telling them they are free to set their own prices, and to amend its compliance program for Australian trade practices law, the ACCC said.

ResMed did not immediately respond to a call for comment.

-By David Fickling, Dow Jones Newswires; +61 2 8272 4689; david.fickling@dowjones.com

Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http://www.djnewsplus.com/access/al?rnd=QNuS73vTbwGle8%2BC70zpfA%3D%3D. You can use this link on the day this article is published and the following day.

(END) Dow Jones Newswires

ResMed Inc. (NYSE: RMD) announced today that its two-for-one stock split of the company's outstanding shares of common stock, payable in the form of a 100% stock dividend was completed on August 30, 2010. The new total shares outstanding doubled to 151,388,240 shares, excluding shares held as treasury stock. The closing price of the company's common stock on the New York Stock Exchange on August 30, 2010 was $60.38. On a split-adjusted basis, the company's closing stock price on August 30, 2010 would have been $30.19. The company's total market capitalization as of August 30, 2010 was approximately $4.6 billion on that date.

Yes! 2:1 split has happened!
Now just waiting for those free shares to show up!

Steady climb pre-split. Financials decent. Should resume upward trend after split.

SYDNEY, Aug 12, 2010 /PRNewswire via COMTEX/ -- ResMed, Inc. (NYSE: RMD), (ASX:
RMD) announced today that the company has been granted a waiver of rules 13.9.4
and 13.9.9 of the Australian Stock Exchange Settlement Operating Rules, in
connection with the stock split announced to the Market on 6 August 2010.

(Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100203/RESMEDLOGO)

As advised in the Company's 6 August announcement:

Stockholders of record on the New York Stock Exchange at the close of trading on
August 17, 2010 will receive one additional share of common stock for each share
held on that date. The common stock will be distributed to shareholders on or
about August 30, 2010, by ResMed's NYSE transfer agent, American Stock Transfer
and Trust Company, LLC. The common stock is expected to begin trading on a
post-split basis on the NYSE beginning on August 31, 2010, or one day following
the distribution date.

Holders of CHESS Depositary Interests (CDIs) on the Australian Stock Exchange
will also receive a bonus issue of one additional CDI for every CDI held on the
ASX record date of August 18, 2010. Unlike the shares on the NYSE, the existing
CDIs will be quoted on an "ex-bonus" basis on August 12, 2010 on the ASX (ASX:
RMD), and bonus CDI's will be quoted on a deferred settlement basis (ASX:
RMDBN). The bonus CDIs will be distributed by ResMed's ASX share registry,
Computershare Limited, on or about August 31, 2010, and normal trading will
begin on the following day.

Due to the difference in market practice between the NYSE and ASX, ResMed
applied for and has been granted a waiver of rules 13.9.4 and 13.9.9 of the ASX
Settlement Operating Rules, allowing it to defer the processing of conversions
(transmutations) between its Common Stock and CDI registers that are lodged in
the period from and including 12 August 2010 up to and including 31 August 2010.
Therefore, no conversions (transmutations) will be processed during this time.
Processing of conversions will re-commence on 1 September 2010.

About ResMed

ResMed is a leading developer, manufacturer and distributor of medical equipment
for the treatment and management of sleep-disordered breathing and other
respiratory disorders. The company is dedicated to developing innovative
products to improve the lives of those who suffer from these conditions and to
increasing awareness among patients and healthcare professionals of the
potentially serious health consequences of untreated sleep-disordered breathing.

Further information can be obtained by contacting Constance Bienfait at ResMed,
Inc., San Diego, on (+ 1 858-836-5971), or Brett Sandercock at ResMed Limited,
Sydney, on (+61 2) 8884-2090; or by visiting the Company's multilingual Web site
at www.resmed.com.

SOURCE ResMed, Inc.

Chart



Looking forward to the split!!

2:1 stock split

Australian sleep management company RESMED INC (ASX:RMD) on Friday booked record revenue and income for the 2010 full financial year and announced a two-for-one stock split. ResMed said that for the year ended June 30, 2010, income from operations was US$240.4 million, and net income was US$190.1 million, an increase of 26 per cent and 30 per cent respectively, compared to the 2009 full financial year.

* Annual revenue in 2010 was US$1.1 billion, up 19 per cent (or 17 per cent on a constant currency basis) over 2009.

* ResMed also announced on Friday that its board of directors had approved a two-for-one stock split of the company's outstanding shares of common stock, payable in the form of a 100 per cent stock dividend.